IPI-145, an oral, potent PI3K-delta inhibitor...

IPI-145, an oral, potent PI3K-d,? inhibitor, appears to be well tolerated and has shown initial clinical activity in pts with iNHL, MCL, and CLL.

Infinity released positive phase 1 data on IPI-145, its oral PI3K-inhibitor aimed at treating hematological malignancies.

The results demonstrated that IPI-145 showed clinical activity in B-cell and T-cell malignancies.

Source Abstract from ASH


Last edited by

1 Reply

  • Hi this may be the breakthrough we all hope for only time will tell

You may also like...